Why Did My Oncologist Choose This Drug and Not the Other One?
Your oncologist's choice is driven mainly by your cancer type's approved indication and your own biomarker results, then by whether a specific combination partner is required — hospital protocol, drug availability and cost usually come after that, not before it. It is a clinical decision built around your reports, not a brand preference, and asking why is a fair question, not an awkward one.
Medically reviewed by Dr. Bharati Devi Gorantla, Medical Oncologist, MBBS · MD · DM (Adyar, Chennai) · ECMO · MRCP SCE (UK) · Last reviewed August 2026
What actually decides which immunotherapy drug my oncologist chose for me?
Five factors decide it, roughly in this order: your cancer type's approved indication, your own biomarker results, whether a required combination partner exists, your hospital's protocol and current drug availability, and finally cost or insurance-panel coverage. The first two are regulatory boundaries, not preferences — a drug that isn't approved for your cancer type or biomarker profile simply isn't an option, however well it worked for someone else's diagnosis.
Most patients asking this question have already found a comparison page online — like the ones linked further down this page — showing two named drugs side by side, and are quietly wondering if their oncologist picked the "wrong" one. In most cases, the two drugs being compared online were never both options for that specific patient to begin with.
A framework for the conversation, not a checklist for negotiation — rows 1 and 2 override the rest whenever they apply.
Is the drug my oncologist picked really just about cost?
Usually not, and it is rarely the first factor. Cost, insurance-panel listings and Aarogyasri coverage sit at the bottom of the decision above — they only start to influence the choice once your indication, biomarker results and any required combination have already narrowed the field to approved options. A cheaper drug that isn't approved for your specific cancer type is not a real alternative, whatever a cost-comparison page online suggests.
That said, cost genuinely does move within the set of approved options, and this has shifted meaningfully in 2026. Nivolumab's Indian patent lapsed in May 2026, with a domestic biosimilar launched in January 2026 at roughly a quarter of the reference product's price (indicative, as of August 2026) — a real reason a hospital's formulary might favour it where it's an approved fit. Pembrolizumab has no biosimilar in India yet, since its patent protection isn't expected to begin lapsing until around 2028-29, so its pricing hasn't moved the same way. Neither figure is a CION price list; actual cost depends on dose, brand or biosimilar, hospital and your overall treatment plan.
Genuine biosimilars entering ahead of patent expiry has also brought reports of counterfeit checkpoint inhibitors in the Indian market — sourcing any of these drugs only through a licensed hospital pharmacy with documented cold-chain handling is a safety matter, not just a cost one.
Can I ask my oncologist for a different immunotherapy drug?
Yes — asking is a reasonable question, not a challenge to your treatment plan. A useful way to ask is "why is this the recommended option for my case, and is there an approved alternative within the same protocol," rather than requesting a specific brand you read about online. Your oncologist can only offer options that are actually approved for your exact diagnosis and biomarker results, so the honest answer may still point back to the same drug — but you are entitled to hear the reasoning, and most oncologists expect the question.
What tends to go less well is requesting a switch mid-cycle based on price alone — how you tolerated earlier doses and the timing between cycles both affect whether a change is even clinically sensible at that point.
Who this explainer is — and isn't — for
This page is for patients and caregivers who have already been offered a specific immunotherapy drug and want to understand, in plain terms, why that one rather than a different one they read about online, saw compared on another page, or heard about from another patient.
It is not: a claim that any named drug is superior to another; a suggestion that switching mid-treatment is simple or always possible; legal or insurance advice; or a substitute for asking your treating oncologist directly. If you are on a clinical trial, the drug and dose are usually fixed by the trial protocol, not by the factors described here — ask your trial coordinator instead. And most people simply curious about immunotherapy, without a confirmed diagnosis and biomarker report, are not yet in a position to be offered any specific checkpoint inhibitor at all.
How do I actually ask, without sounding like I'm second-guessing my oncologist?
Ask about the reasoning behind your specific case, not about a specific brand you'd prefer — the first invites an explanation, the second invites a flat no. A few versions that tend to open a genuine conversation:
- "Why is this the recommended drug for my cancer type and biomarker results?" — asks for the reasoning, not a swap.
- "Is there an approved biosimilar or alternative within the same protocol that could reduce the cost?" — surfaces real options if any exist.
- "If my insurance panel or Aarogyasri doesn't cover this brand, is there an approved substitute?" — routes the cost conversation to the right people.
- "If I had a reaction to an immunotherapy drug before, does that change which one is being offered now?" — surfaces safety history your oncologist may already be factoring in.
Does asking about switching drugs delay or restart my treatment?
Asking does not delay anything — it is a conversation, not a request to pause treatment. A genuine change, if your oncologist agrees one is appropriate, takes a little coordination (updated orders, insurance pre-authorisation, confirming pharmacy stock) but is planned around your existing treatment calendar rather than restarting your care.
A previous reaction, or how you responded to earlier cycles, is a genuine factor in whether a change makes clinical sense — that judgement belongs to your treating oncologist, not a general explainer like this one.
Why This Drug and Not the Other One: Frequently Asked Questions
What actually decides which immunotherapy drug my oncologist chooses?
Five factors decide it, roughly in this order: your cancer type's approved indication, your own biomarker results, whether a required combination partner exists, your hospital's protocol and current drug availability, and finally cost or insurance-panel coverage. The first two are regulatory boundaries, not preferences — a drug that isn't approved for your cancer type or biomarker profile simply isn't an option, no matter how well it worked for someone else's diagnosis.
Is the choice of immunotherapy drug mostly about cost?
Usually not, and it is rarely the first factor. Cost, insurance-panel listings and Aarogyasri coverage sit at the bottom of the decision — they only start to matter once your indication, biomarker results and any required combination have already narrowed the field to approved options. Two drugs that both worked for a friend's cancer may not both be approved for yours, which is a bigger factor than either drug's price.
Can I ask my oncologist for a different immunotherapy drug?
Yes — asking is a reasonable question, not a challenge to your treatment plan. A useful way to ask is "why is this the recommended option for my case, and is there an approved alternative within the same protocol," rather than requesting a specific brand you read about online. Your oncologist can only offer options that are approved for your exact diagnosis and biomarker results, so the answer may still point back to the same drug — but you are entitled to hear the reasoning.
Will asking about a different drug delay my treatment?
Asking the question itself does not delay anything — it is a conversation, not a request to pause treatment. A genuine change, if your oncologist agrees one is appropriate, does take a short amount of coordination (updated orders, insurance pre-authorisation, pharmacy stock), but this is planned around your existing treatment calendar wherever possible rather than restarting your care from scratch.
If I can't afford the drug I was offered, is there always a cheaper option?
Not always, but sometimes — and it is worth asking specifically. Some checkpoint inhibitors now have domestic biosimilar versions in India at a lower price than the reference product (nivolumab is the clearest example, with a biosimilar launched in January 2026), while others do not yet have one. Whether a lower-cost approved alternative exists depends on the specific drug and your diagnosis, not on cost negotiation alone — ask your oncologist and your hospital's insurance desk together, before assuming none exists or that price is the only consideration.